Literature DB >> 21799247

A disease state fingerprint for evaluation of Alzheimer's disease.

Jussi Mattila1, Juha Koikkalainen, Arho Virkki, Anja Simonsen, Mark van Gils, Gunhild Waldemar, Hilkka Soininen, Jyrki Lötjönen.   

Abstract

Diagnostic processes of Alzheimer's disease (AD) are evolving. Knowledge about disease-specific biomarkers is constantly increasing and larger volumes of data are being measured from patients. To gain additional benefits from the collected data, a novel statistical modeling and data visualization system is proposed for supporting clinical diagnosis of AD. The proposed system computes an evidence-based estimate of a patient's AD state by comparing his or her heterogeneous neuropsychological, clinical, and biomarker data to previously diagnosed cases. The AD state in this context denotes a patient's degree of similarity to previously diagnosed disease population. A summary of patient data and results of the computation are displayed in a succinct Disease State Fingerprint (DSF) visualization. The visualization clearly discloses how patient data contributes to the AD state, facilitating rapid interpretation of the information. To model the AD state from complex and heterogeneous patient data, a statistical Disease State Index (DSI) method underlying the DSF has been developed. Using baseline data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ability of the DSI to model disease progression from elderly healthy controls to AD and its ability to predict conversion from mild cognitive impairment (MCI) to AD were assessed. It was found that the DSI provides well-behaving AD state estimates, corresponding well with the actual diagnoses. For predicting conversion from MCI to AD, the DSI attains performance similar to state-of-the-art reference classifiers. The results suggest that the DSF establishes an effective decision support and data visualization framework for improving AD diagnostics, allowing clinicians to rapidly analyze large quantities of diverse patient data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21799247     DOI: 10.3233/JAD-2011-110365

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  36 in total

1.  A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease.

Authors:  Shaker El-Sappagh; Jose M Alonso; S M Riazul Islam; Ahmad M Sultan; Kyung Sup Kwak
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

Review 2.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

Review 3.  Advancing Alzheimer's research: A review of big data promises.

Authors:  Rui Zhang; Gyorgy Simon; Fang Yu
Journal:  Int J Med Inform       Date:  2017-07-24       Impact factor: 4.046

Review 4.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

5.  Software tool for improved prediction of Alzheimer's disease.

Authors:  Hilkka Soininen; Jussi Mattila; Juha Koikkalainen; Mark van Gils; A Hviid Simonsen; Gunhild Waldemar; Daniel Rueckert; Lennart Thurfjell; Jyrki Lötjönen
Journal:  Neurodegener Dis       Date:  2011-12-09       Impact factor: 2.977

Review 6.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

Review 7.  A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Biol Psychiatry       Date:  2013-11-28       Impact factor: 13.382

8.  The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease.

Authors:  Kari Antila; Jyrki Lötjönen; Lennart Thurfjell; Jarmo Laine; Marcello Massimini; Daniel Rueckert; Roman A Zubarev; Matej Orešič; Mark van Gils; Jussi Mattila; Anja Hviid Simonsen; Gunhild Waldemar; Hilkka Soininen
Journal:  Interface Focus       Date:  2013-04-06       Impact factor: 3.906

Review 9.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

10.  Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool.

Authors:  Yawu Liu; Jussi Mattila; Miguel Ángel Muñoz Ruiz; Teemu Paajanen; Juha Koikkalainen; Mark van Gils; Sanna-Kaisa Herukka; Gunhild Waldemar; Jyrki Lötjönen; Hilkka Soininen
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.